Please login to the form below
beta thalassaemia
This page shows the latest beta thalassaemia news and features for those working in and with pharma, biotech and healthcare.
Vertex to lead development of CRISPR Therapeutics-partnered gene therapy
According to the companies, seven patients with transfusion-dependent beta thalassaemia (TDT), including three who have either a severe or b0/b0 genotype, were transfusion independent at the last follow-up.
Latest news
-
bluebird bio anticipates lift of clinical holds on LentiGlobin in mid-2021
210 clinical studies of LentiGlobin for SCD, as well as the holds on the HGB-207 and HGB-212 studies of beti-cel for beta-thalassaemia. ... In relation to its beta-thalassaemia gene therapy Zynteglo, bluebird bio said this would be withdrawn from the
-
Vertex gains FDA fast track designation for diabetes stem cell therapy
This includes CTX001 – an investigational gene therapy – which has already demonstrated promising early data in transfusion-dependant beta thalassaemia (TDT) and severe sickle cell disease (SCD) patients.
-
bluebird bio says AML case "very unlikely" to be related to gene therapy LentiGlobin
the FDA that we believe these results support lifting the clinical holds on our beta-thalassemia and sickle cell disease programmes,” he added. ... bluebird bio said that, based on the available data, it has initiated discussions with regulators to
-
bluebird bio posts modest Q4 revenue growth as it continues investigation into troubled LentiGlobin
In addition to the clinical holds, bluebird has also temporarily paused marketing of the gene therapy in Europe, where it is currently marketed as Zynteglo for the treatment of beta thalassaemia. ... Zynteglo was initially approved in the EU in 2019,
-
NICE turns down bluebird bio’s gene therapy Zynteglo
The UK’s National Institute for Health and Care Excellence (NICE) has rejected bluebird bio’s gene therapy Zynteglo for patients with transfusion-dependent beta-thalassaemia (TDT) in draft guidance. ... The one-off gene therapy was approved by the
bluebird bio anticipates lift of clinical holds on LentiGlobin in mid-2021
Vertex gains FDA fast track designation for diabetes stem cell therapy
More from news
Approximately 7 fully matching, plus 25 partially matching documents found.
Latest Intelligence
-
Case-study for thalassaemia: Dimitri Azzopardi
An in-depth look at beta thalassaemia for Rare Disease Day. Beta thalassaemia major is a serious, lifelong genetic blood disorder. ... At least 75, 000 children are born. with thalassaemia worldwide every year, of which 10, 000 have the debilitating form
-
20 for 2020 – Five pharma companies to watch
treatment ozanimod and myelodysplastic syndromes/beta thalassaemia candidate luspatercept – to deliver on their potential.
Case-study for thalassaemia: Dimitri Azzopardi
20 for 2020 – Five pharma companies to watch
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Senior Account / Programme Manager - MedComms - Buckinghamshire
-
Highly Competitive Remuneration packages
-
Account Manager
-
Competitive Salary
- Senior Account Director & Associate Director - Healthcare Ad...
-
Highly Competitive Salary, Bonus &Benefits
- Account Manager / Senior Account Manager - Creative MedComms - C...
-
Excellent Remuneration
-
Associate Account Director
-
Competitive Salary
- Senior Medical Writer– Medical Education – Oxford - London
-
Excellent Remuneration Package
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
- Head of Strategic Planning, Healthcare Advertising/ Brand comms,...
-
Six figure salary
- Medical Writer, Senior Medical Writer, Principal Medical Writer,...
-
Highly Competitive Salary, Bonus &Benefits
- Senior & Principal Medical Writer
-
Competitive Salary Offered
-
Senior Medical Writer
-
Competitive Salary
-
Senior Account Executive
-
Competitive Salary
- Senior Account Manager/ Account Director
-
Competitive Salary Offered
- Medical Writers (All levels) Editorial / Scientific Leads & ...
-
Highly Competitive Remuneration packages
- Editor & Senior Editor - Medical Communications - Home Based
-
Highly Competitive Salary, Bonus &Benefits
-
Medical Editor
-
Competitive Salary
-
Publications Director
-
Competitive Salary
- Account Manager - Creative Healthcare Communications - South Wes...
-
Excellent Remuneration
- Client Services Director – London or Home Based – Medical Commun...
-
Highly Competitive Salary, Bonus &Benefits
- Group Account Director, Healthcare Advertising/ Brand comms, Lon...
-
8 month contract up to £90K
-
Account Management
-
Competitive Salary Offered
- Merck & Co reveals plans for women’s health spinoff Organon
- Novavax is close to finalising a COVID-19 vaccine supply deal with the EU
- EMA launches rolling review of GSK/Vir Biotech’s mAb for early COVID-19
- bluebird bio aiming to separate business units by year-end
- FDA accepts BMS’ investigational cardiovascular drug mavacamten for review
- Single dose of COVID-19 vaccines ‘significantly’ reduces infections
- Pfizer asks UK's MHRA to approve its COVID-19 vaccine in adolescents
- Clark Health promotes Siân Hurst to managing director role
- ENGINE MHP+Mischief bolsters healthcare comms expertise with new senior hires
- New court filing alleges Sanofi destroyed emails relating to Zantac recall
- Pfizer warns that IP waiver for COVID-19 vaccines may invite ‘copycat medicines’
- EMA introduces new measures to enable flexibility for non-COVID-19 procedures
No results were found
PMHub
Say Communications
Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...
Latest intelligence
- How innovating study sites can improve patient recruitment efficiency
- There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
- Avoiding A Series of Unfortunate Events: launch lessons from lockdown
- Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
- 6 reasons patients drop out of clinical trials and 6 ways to fix it
- If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....
